Kornimate/medical-research-clean huggingface dataset:
topical and local txa in facelifts - a randomized controlled double blinded study

Conditions: Hemophilia; Hemorrhage; Facelift Surgery

Summary: tranexamic acid (txa) is a fibrinolytic inhibitor which prevents prolonged bleeding by interfering with fibrin clot breakdown by competitively binding to lysine receptors on plasminogen; this prevents the conversion of plasminogen to plasmin. txa will be applied to a randomly assigned side of the face during facelift surgery. the intervention groups will include 1% txa mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine, 3% txa on txa-soaked pledgets applied for 10 minutes, and 1% txa with local plus 3% txa-soaked pledgets. each treatment arm will be compared to saline in place of txa on the contralateral side of the face. although txa has been widely used in surgical fields for decades and is officially recommended by agencies such as acog for use during maternal hemorrhage, its current fda approval only pertains to oral txa for heavy menstrual bleeding and iv use for patients with hemophilia to prevent or reduce hemorrhage (cite). the main concern with intravenous txa is the increased risk for the potential formation of blood clots, mainly in patients with clotting disorders, such as facor v leiden, and patients on estrogen containing medication. a recent systemic review with metanalysis by wang et.al contained a total of 2150 patients receiving iv txa while undergoing plastic surgery concluded that use of iv txa does not lead to increased adverse events.\[12\] given the low rate of adverse events while using txa systemically, this protocol's application of txa topically and/or locally negates the risk for any potential systemic adverse effects. no systemic adverse effects have been reported in studies examining local txa in facial plastic surgery to date.


Eligibility criteria:
inclusion criteria: * eligible participants will consist of all regular clinic patients who elect and are deemed fit by the surgeon to undergo facelift surgery, including patients undergoing ancillary procedures * age 18 and older * english speaking. exclusion criteria: * younger than 18 * previously had an adverse reaction to tranexamic acid * non-english speaking * patients who elect not to participate or withdraw from the study.
comparison of chest ct findings related to covid-19 with rsna and bsti guidelines

Conditions: Covid19; Infection Viral; CT Scan

Summary: to present the first admission chest computed tomography (ct) findings of patients followed up with a diagnosis of covid-19, and to compare the two classification systems by evaluating these findings according to the bsti and rsna guidelines.

a total of 764 adult patients who were diagnosed with covid-19 inpatient of researchers' hospital 2020 were included in this study. the findings were recorded as typical, indeterminate, and atypical by the rsna guidelines and as classical covid-19, possible covid-19, indeterminate, and non-covid-19 by the bsti classification. the data obtained according to both classification systems were compared with each other.

Eligibility criteria:
inclusion criteria: 1. who had single negative rt-pcr 2. non-optimal chest ct , insufficient data 3. \<18 age of year 4. thoracic trauma 5. chest ct negative exclusion criteria: 1. rt-pcr positive and chest ct positive findings 2. at least two rt-pcr negative and chest ct positive findings 3. \>18 age of year

Keywords: coronavirus computed thomography pcr
evaluating pediatric ivermectin in children under 15 kg (epic-15)

Conditions: Scabies

Summary: the epic-15 trial will evaluate the safety, pharmacokinetics, acceptability, and efficacy of pediatric ivermectin (child-ivitab) in scabies infected children weighing 5 to less than 15 kg. this trial will support future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15 kg to treat numerous ntds, allowing this young age group equitable access to the numerous benefits of pediatric ivermectin therapy


Eligibility criteria:
inclusion criteria: * male or female child weighing 5 to \<15 kilograms * ≥3 months old * scabies infestation * available to attend all study visits * parents/guardians/carers able to provide written informed consent exclusion criteria: the participant may not enter the trial if any of the following apply: * a history of renal or hepatic impairment. * any other significant disease or disorder (e.g. moderate or severe malnutrition) which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. * participants who are participating or have participated in another research trial involving an investigational product in the past 12 weeks. * children with crusted/norwegian scabies or severe secondary bacterial infections (e.g. sepsis) * children who have taken ivermectin within the last month * children with known allergies to ivermectin or excipients * loa loa infection risk, assessed based on travel history to endemic areas * use of prescription (especially cyp3a4 inhibitors or inducers) or non-prescription drugs (except paracetamol at doses of up to 90 milligrams/kg/day), including vitamins (especially vitamin c), herbal and dietary supplements (including st. john's wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 times the drug half-life (whichever is longer) prior to the first dose of study medication until the completion of the follow-up procedure, unless in the opinion of investigator, the medication will not interfere with the study procedures or compromise participants safety; the investigator will take advice from the manufacturer representative as necessary. * the investigator, health care provider or study staff feel that the participant is not suitable for study participation due to chronic illness, suspected underlying illness, or concerns that the participant will not adhere to follow-up schedule. * being born prematurely. * previously enrolled into this study

Keywords: ivermectin pediatric child-ivitab
educating patients on management of overactive bladder: written versus verbal instructions

Conditions: Overactive Bladder

Summary: background: overactive bladder (oab) is a common condition among postmenopausal women, requiring a multifaceted treatment approach that requires patient retention of information given to them in clinic. recall of recommendations is a key component of compliance. supplemental educational tools such as handouts and audiovisual information have been investigated for their ability to improve patients' recall of information and increase satisfaction with the clinical encounter. objective: to determine if a written list of seven management strategies for overactive bladder leads to improved immediate and delayed recall of these recommendations in postmenopausal women presenting with oab compared to a traditional verbal discussion. methods: in this single-blind, randomized controlled trial, patients' immediate and delayed (2-week) recall of seven oab management strategies will be compared between two groups. the intervention group will receive a handwritten list during their verbal discussion of oab treatment while the control group will receive standard care (verbal discussion only). immediate and delayed recall will be assessed by a member of the study team who has been blinded to participants' group assignments. results: the results of this study may guide clinicians in the most effective mode of providing treatment recommendations to post-menopausal patients with oab.


Eligibility criteria:
inclusion criteria: * new diagnosis of overactive bladder * post-menopausal exclusion criteria: * pre-existing diagnosis of dementia or other cognitive disorders * patients with mixed incontinence * non-english speaking * patients with contraindications to taking vaginal estrogen or anticholinergic medications
vitamin d supplementation on in major orthopedic surgery

Conditions: Hypovitaminosis D; Cardiovascular Diseases

Summary: prospective, monocentric study in open, aimed at evaluating the effects of supplementation with calcifediol on left ventricular function parameters in cardiopathic subjects undergoing major orthopedic surgery.

population of the study: 47 cardiopathic patients with hypovitaminosis d supplemented with calcifediol to reach vitamin d levels\> 30 ng / ml within 6 months. the purpose of this study is to evaluate the improvement of the ejection fraction or gls (global longitudinal strain) calculated by speckle tracking at 6 months in cardiopathic patients with vitamin d deficiency during functional recovery after major orthopedic surgery.

Eligibility criteria:
inclusion criteria: * age: \> or equal to 55 years, \< or equal to 85 years * cardiopathic patients (including hypertension) who must undergo major orthopedic surgery at our site * patients with diagnosis: hypovitaminosis d exclusion criteria: * presence of neoplasm * endocrinological pathologies excluding diabetes mellitus * advanced chronic renal failure (gfr \< 35 ml/min) * pregnant women * impossibility to participate to the rehabilitation protocol or to perform the established controls
on top of everything

Conditions: Mental Health; Youth; Mindfulness; Stress

Summary: our primary aim of this trial is to evaluate the effectiveness of a teacher training programme to teach mindfulness as part of regular classroom teaching in the total population of students in danish upper secondary schools and schools of health and social care, respectively, on students' self-reported mental health at six-month follow-up. our secondary aim is to evaluate the effectiveness of the teacher training programme to teach mindfulness in a vulnerable subgroup of students on their self-reported mental health at three and six months after baseline.

the study is designed as a pragmatic cluster randomised two-arm trial including 43 danish schools (30 upper secondary schools and 13 schools of health and social care). the schools included a total of 76 school teachers for teacher training (44 teachers from upper secondary schools and 32 teachers from schools of health and social care). each included teacher will be asked to recruit a class of students (15-30 students) to test the effectiveness of the modified mbsr programme (in total approx. 1.000 students).

Eligibility criteria:
inclusion criteria: * all students in the enrolled school classes exclusion criteria: * none

Keywords: school-based intervention population-based preventive strategy public health
cerebral blood flow (cbf) disturbances following traumatic brain injury (tbi) and subarachnoid hemorrhage (sah)

Conditions: Traumatic Brain Injury; Subarachnoid Hemorrhage

Summary: it is a "proof of concept" study, aimed to evaluate whether the "optimal cpp", defined by the best prx, corresponds to the acceptable cbf values in patients affected by cbf disfunction caused by tbi or sah.

cerebral blood flow (cbf) disturbances are common following tbi and sah. the occurrence of cbf derangements is detrimental for the neurological outcome in both settings, but the management of neurologically critically ill patients does not involve cbf measure routinely. cerebrovascular autoregulation, can be assessed by the cerebrovascular pressure-reactivity index (prx) that point out the response of icp to spontaneous changes in arterial blood pressure (abp). autoregulation has been proven to be a powerful protective mechanism. adding together the information on cbf and autoregulation, might drive clinical strategy in exceptionally noteworthy and innovative way. currently, a novel thermal diffusion (tdp) microprobe has been introduced for the continuous bedside monitoring of regional cbf: tdp is a promising technique in the reliable detection of flow derangements at the patient's bedside. it is a "proof of concept" study, aimed to evaluate whether the "optimal cpp", defined by the best prx, corresponds to the acceptable cbf values. patients admitted with the diagnosis of tbi and sah in for whom icp and cpp needs to be monitored on clinical ground will be also monitored with a td probe and routinely tested for cerebral autoregulation, thus obtaining the cbf corresponding at a given the "best cpp" and autoregulation status. continuous cbf measures and prx monitoring may allow more accurate identification and early detection of adverse cerebral conditions. this approach may bring us a step closer to the goal of outcome improvements in patients suffering from intracranial insult.

Eligibility criteria:
inclusion criteria: * patients admitted with the diagnosis of sah and requiring intensive monitoring, and icp probe. * patients admitted diagnosis of severe tbi and requiring intensive monitoring, and icp probe. exclusion criteria: * age \< 16 years * previous sah, brain surgery, stroke, brain trauma

Keywords: sah tbi
ablator brazil - ablation observational study (registry)

Conditions: Atrial Fibrillation

Summary: the purpose of this registry is to assess the performance and clinical effectiveness of a combination of st. jude medical (sjm)/abbott mapping and ablation products in the treatment of subjects with atrial fibrillation (af).

the objectives of this registry are the following: * to confirm patient safety as part of the post market surveillance study. * to assess performance of a combination of sjm products during procedures. * to assess the learning curve with a combination of sjm products. * to collect operator feedback on a combination of sjm products. all patients from participating sites who are indicated for an atrial fibrillation ablation procedure and willing to provide written informed consent may be enrolled in this registry. in order to ensure a minimum level of uniformity across site practices and to enable comparison of acute and long-term effectiveness as well as procedure efficiency according to technique used, a combination of 2 types of devices from the pre-specified list must be used to be eligible in this registry.

Eligibility criteria:
inclusion criteria: * all patients who are indicated for an atrial fibrillation ablation procedure. exclusion criteria: * pregnant women
ketotifen/naphazoline ophthalmic solution in the conjunctival allergen challenge model of acute allergic conjunctivitis.

Conditions: Allergic Conjunctivitis

Summary: the purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (cac)-induced allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: * positive history of ocular allergies and positive skin test reaction to cat hair, cat dander, grasses, ragweed, and/or trees within the past 24 months. * calculated best-corrected visual acuity of 0.7 logmar or better in each eye as measured using the etdrs chart. * positive bilateral conjunctival allergen challenge(cac) reaction within 10 minutes of instillation of the last titration of allergen at visit 1. * positive bilateral cac reaction for at least 2 out of 3 time points at visit 2. exclusion criteria: * known contraindications or sensitivities to the study medication or its components. * any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters. * use of disallowed medications during the period indicated prior to study enrollment or during the study.
dynamic preload parameters during liver transplantation

Conditions: Liver Cirrhosis

Summary: the arterial system compliance is compromised in liver cirrhotic patients. dynamic preload variables are either pressure-based (e.g.pulse pressure variation; ppv), flow-based (e.g. stroke volume variation; svv), or volume-based (plethysmographic variability index; pvi). it is not yet clear that dynamic preload parameters based on which mechanism will be accurate to predict fluid responsiveness in the cirrhotic patients. therefore, this study aimed to claried which dynamic preload parameters would be more accurate during the liver transplantation.

fluid management is crucial during liver transplantation. patients with cirrhosis and portal hypertension have an altered blood volume distribution and pooling in the splanchnic circulation. excess administration of intravenous fluid may increase portal hypertension due to splanchnic venous congestion and may also aggravate coagulopathy by dilution. on the other hand, fluid restriction may risk systemic and especially renal hypoperfusion. traditional static fluid parameter, such as central venous pressure, pulmonary artery occlusion pressure, have been reported inaccurate to predict fluid responsiveness. in comparison, the recent developed dynamic fluid parameters based on heart-lung interaction were reported to be good preload indicators in a variety of different surgical settings. however, the validity of such dynamic fluid parameters is highly dependent on the arterial system compliance is compromised in liver cirrhotic patients. dynamic preload variables are either pressure-based (e.g.pulse pressure variation; ppv), flow-based (e.g. stroke volume variation; svv), or volume-based (plethysmographic variability index; pvi). it is not yet clear that dynamic preload parameters based on which mechanism will be accurate to predict fluid responsiveness in the cirrhotic patients. therefore, this study aimed to claried which dynamic preload parameters would be more accurate during the liver transplantation.

Eligibility criteria:
inclusion criteria: * end stage liver disease patients scheduled for liver transplantation in national taiwan university hospital exclusion criteria: * allergic reaction * preexisting arrythmia

Keywords: pulse pressure variation stroke volume variation plethysmographic variation index fluid responsiveness
gene expression in predicting outcome in samples from patients with high-risk neuroblastoma

Conditions: Neuroblastoma

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in rna and predict how patients will respond to treatment. it may also help doctors find better ways to treat cancer. purpose: this research trial studies gene expression in predicting outcomes in samples from patients with high-risk neuroblastoma.

objectives: * to test the correlation of a previously published microarray gene expression signature with the gene expression obtained with the ncounter™ analysis system using rna isolated from formalin-fixed, paraffin-embedded (ffpe), high-risk neuroblastoma samples. * to construct, test, and validate a novel robust classifier that can be readily integrated into the clinic. outline: this is a multicenter study. rna samples extracted from paraffin-embedded tissue are analyzed for gene signature expression levels by ncounter™ analysis system and correlated with published microarray expression data. results are then used to develop a refined gene-expression-profile classifier of ultra high-risk neuroblastoma.

Eligibility criteria:
disease characteristics: * formalin-fixed paraffin-embedded tumor sections linked to clinical and outcome data collected from high-risk neuroblastoma patients (n=100) treated at the university of chicago, st. jude children's research hospital, children's memorial hospital, or texas children's hospital patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: disseminated neuroblastoma localized unresectable neuroblastoma recurrent neuroblastoma regional neuroblastoma stage 4s neuroblastoma
metabolic mapping and cardiac resynchronization

Conditions: Heart Failure

Summary: the purpose of this study is to gather information on the safety and effectiveness of cardiac resynchronization therapy (crt) in patients who have mild heart failure (hf) and left bundle branch block (lbbb).


Eligibility criteria:
inclusion criteria: * left ventricular ejection fraction (lvef) 35%-50% * new york heart association (nyha) class i-ii * qrs duration of ≥120ms * left bundle branch block (lbbb) * patient is able to receive a transvenous pectoral crt implant * patient is able to sign informed consent * two echocardiograms are required to confirm a stable reduced lvef * patient is on optimal and stable medical therapy (ace inhibitor or angiotensin ii type 1 (at1 )blocker, beta blocker, etc. over the last 6 months) exclusion criteria: * advanced comorbid conditions with life expectancy \<1 year * patient is \<18 of years of age * patient has a crt device * female patients who is pregnant or not on a reliable form of birth control. women of childbearing potential are required to have negative pregnancy test within the 7 days prior to device implant * unwilling or unable to return for required follow-up visits * patient decides study participation is cost-prohibited
effects of a dementia-friendly program

Conditions: Delirium; Cognitive Impairment; Dementia

Summary: frail older persons with cognitive impairment are at special risk of experiencing delirium during acute hospitalisation. the purpose of this study was to investigate whether a dementia-friendly hospital program contributes to improved detection and management of patients with cognitive impairment and delirium.

study design this study, has a non-equivalent control group design and a historical control group. the control group received usual care and the experimental group received usual care plus the dementia-friendly program. one group received care after implementing the dementia-friendly hospital program. the study is performed at two medical wards at a large acute-care hospital in norway. a medical pulmonary ward and a cardiac ward participated. data collection: demographic data included age, gender, place of residence (home, adapted housing, institution), and family/relative network, and were obtained upon admission to the study. medical data included cause of admission, active medical diagnoses, medications and medical treatment, and were obtained both at admission and from their electronic medical records after discharge. cognitive impairment and delirium were assessed with two different screening tools: the four assessment test (4at) and the confusion assessment method (cam). for all patients with a positive 4at (≥1) or identified cognitive impairment during their hospital stays, a thorough review of the patient's journal was conducted upon discharge to record if, in case of yes, which type of preventive or treatment measures according to the dementia-friendly program, the patients had received during their stays.

Eligibility criteria:
inclusion criteria: * patients ≥75 years * acute admission to the cardiac or pulmonary wards. * patient who has given informed written consent, or proxy consent from relatives for patients who lacked cognitive capacity. exclusion criteria: * readmitted patients enrolled in a previous hospital stay. * patients who do not have sufficient verbal function or hearing to communicate * patients in a coma or too ill to participate * patients who are isolated * patients who do not wish to participate or relatives who do not want the patient to participate, in the cases where the patient lacked cognitive capacity to consent.